Zimbabwe has turned down a major American health deal worth $367m (272 million pounds) spanning five years because of Washington's demand for confidential biological samples.
The decision came to light after a official document dated December was disclosed, which showed Head of State Emmerson Mnangagwa deemed the agreement was "unbalanced".
An official spokesman later explained that the United States was requesting biological samples for research and commercial purposes while was not willing to share the benefits from any future vaccines.
"We must now begin the challenging and unfortunate process of ending our support in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy noted the United States had furnished over $1.9bn for health programmes to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has called for more talks to find a agreement acceptable to all parties so the country's critical HIV treatment initiative can proceed.
Wider Context
Zimbabwe's decision follows a similar situation in Kenya, where a high court halted a similar deal with the US following legal challenges were raised about the security of citizens' medical information.
After resuming the presidency recently, US President Donald Trump has drastically cut overseas assistance and closed the US Agency for International Development (USAID).
USAID had managed aid for the American government, but Trump stated its spending was "wasteful" and his administration was seeking government-to-government deals to enhance openness and accountability.
As per reports, Sixteen African countries have so far agreed to these new health pacts, representing more than $18.3bn of fresh investment.
Details of the Rejected Deal
The funds for Zimbabwe was intended to supported "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We believe this collaboration would have delivered extraordinary benefits for the people of Zimbabwe, especially the 1.2 million men, women and children currently receiving HIV treatment through US-supported programmes," the Ambassador added.
However, official spokesman Nick Mangwana said the arrangement was "asymmetrical".
"Our nation was requested to surrender its biological resources and data indefinitely, without any equivalent guarantee of benefiting from any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that could be developed from that shared data," his statement read.
"Put simply, our nation would provide the basic resources for medical research without any certainty that the final treatments would be accessible to our population should a new disease outbreak emerge."
Sovereignty and International Frameworks
Mangwana further noted that the American exit from the global health body and its pursuit of bilateral health agreements were upending frameworks already established via the global health agency.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing system designed to deal with future pandemics.
"This mechanism is designed to guarantee that when a nation contributes its information, the benefits – including medicines and cures – are shared equitably, not commercialised solely by those with the funds to develop them."
Zimbabwe's reservations over the US deal "should not be misconstrued as hostility towards the US," Mangwana stressed.
"We are open to further discussions with our American counterparts on how future co-operation might be structured in a way that respects the sovereignty and interests of both nations."
Medical Community Response
Medical experts said it acknowledged the government's concerns, but suggested that talks need to persist given that a large portion of the country's Aids initiatives relied on international support.
"If technical issues exist, including those involving information security or implementation frameworks, these can often be addressed through detailed discussion and mutually agreed protections," it commented.
The situation highlights the ongoing debate between accepting crucial international aid and safeguarding a country's data in an increasingly data-driven world.